Since the biosimilars market is still in its infancy stage, biopharmaceutical companies that are attempting to enter space are encountering a variety of distinct challenges. Global regulations not only remain complicated, but they also continue to evolve and differ across certain regions due to a variety of infrastructural issues. Biosimilars is predicted to be a multi-billion-dollar industry in the next few years, so those biopharmaceutical companies that implement the right commercial strategies will have tremendous opportunities to gain shares of […]